Studies: Pazopanib vs. Placebo (AGO-Ovar 16)

ID Trial

110655

EudraCT number

2008-004672-50

Clinicaltrials.gov identifier

NCT00866697

Description

A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status

closed

Disease

Disease Stage  
ovarial cancer metastatic

Treatment arms

Name Description  
Arm A Panzopanib 800 mg pro Tag für 12 Monate
Arm B Placebo

Coordinating investigator

No data

Principal investigator

Prof. Dr. T. Park-Simon
Medizinische Hochschule Hannover
Klinik für Frauenheilkunde und Geburtshilfe
Carl-Neuberg-Str. 1
30625 Hannover
Germany

Study nurse

H. Schuster
Medizinische Hochschule Hannover
Klinik für Frauenheilkunde und Geburtshilfe
Carl-Neuberg-Str. 1
30625 Hannover
Germany
Phone: 6046
Email Schuster.Hiltrud@mh-hannover.de